Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

This study has been terminated.
(slow enrollment)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Ruth He, Georgetown University
ClinicalTrials.gov Identifier:
NCT00881621
First received: April 13, 2009
Last updated: March 23, 2014
Last verified: March 2014

April 13, 2009
March 23, 2014
August 2009
December 2012   (final data collection date for primary outcome measure)
Overall survival [ Time Frame: 2.5 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00881621 on ClinicalTrials.gov Archive Site
  • Clinical benefit response [ Time Frame: 2.5 years ] [ Designated as safety issue: No ]
  • Objective Response [ Time Frame: 2.5 years ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Phase II Study of Lapatinib and Capecitabine in 2nd Line Treatment of Locally Advanced/Metastatic Pancreatic Cancer

Patients are being asked to participate in this study who have locally advanced or metastatic pancreatic cancer (cancer of the pancreas that has spread to another part of the body) that has gotten worse after first-line chemotherapy.

The purpose of this study is to see if the drugs, Capecitabine and Lapatinib (two chemotherapy agents), prolong survival and improve quality of life as compared to supportive care alone.

Lapatinib in combination with a drug called capecitabine, has been approved by the Food and Drug Administration (FDA) for the treatment of metastatic breast cancer. It has not yet been approved to treat this type of cancer. Both of these drugs are pills.

This research is being done because it is not known if the combination of Capecitabine and Lapatinib is better than supportive care alone for pancreatic cancer.

This is an open-label single-arm Phase II trial for patients with metastatic pancreatic cancer who have failed first line Gemcitabine-based therapy. Patients will be treated with a combination of Capecitabine and Lapatinib, a dual tyrosine-kinase inhibitor of EGFR and HER-2.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pancreas Cancer
Drug: Lapatinib and Capecitabine
Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
Other Names:
  • Tykerb
  • GW572016
Experimental: Lapatinib and Capecitabine
Treatment
Intervention: Drug: Lapatinib and Capecitabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
17
June 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the pancreas
  • Prior failed 1st line gemcitabine therapy for metastatic disease or relapsed within six months of completion of gemcitabine adjuvant therapy
  • Prior capecitabine or 5fu is allowed in the setting of radiation
  • Must either be able to swallow or receive enteral nutrition via gastrostomy feeding tube
  • Cardiac ejection fraction within institutional range of normal as measured by echocardiogram
  • ECOG performance status 0-2
  • Signed informed consent form
  • Adequate hepatic, bone marrow, and renal function

Exclusion Criteria:

  • Any prior treatment with lapatinib, or any anti-HER2 treatment or any anti-EGFR treatment
  • Not recovered from adverse events to a toxicity grade </= 1 due to prior chemotherapy
  • More than one prior chemotherapy regimens
  • Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis
  • HIV positive on antiretroviral therapy
  • Pregnant or lactating
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or capecitabine
  • Malabsorption syndrome or uncontrolled inflammatory GI disease (Crohn's or ulcerative colitis)
  • Known history of uncontrolled or symptomatic angina, arrhythmia, or congestive heart failure
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/ social situations that would limit compliance with study requirements
  • Known dihydropyrimidine dehydrogenase deficiency
  • Concurrent malignancy unless the subject has been curatively treated and disease free for >/= 2 years or the cancer was non-melanoma skin cancer or early cervical cancer.
  • Creatinine clearance < 30 mL/min
  • Absolute neutrophil count < 1500, platelets < 75,000
  • Transaminases > 3.0 times the upper limit of normal, except in known hepatic metastasis, wherein they must be < 5.0 times the upper limit of normal
  • Total bilirubin > 1.5 times the ULN, > 2.5 x ULN if patient has Gilbert's syndrome
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00881621
011438, IND #103,981, 2008-437
Yes
Ruth He, Georgetown University
Georgetown University
GlaxoSmithKline
Principal Investigator: Ruth He, MD, PhD Georgetown University
Georgetown University
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP